Clinical Trial Update: Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of osimertinib and abemaciclib in patients with EGFR-mutant non-small cell lung cancer after osimertinib …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: University of California, San Diego | Conditions: Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING